

R&D PORTFOLIO June 2024 – 13 treatments delivered

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION	
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access	
Sleeping sickness							Acoziborole +		Fexinidazole for <i>T.b. gambiense</i> * + Fexinidazole for <i>Tb. rhodesiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*	
Leishmaniasis	Screening			DNDI-6174 +	DNDI-6148 +	LXE408 Novartis for VL +	Miltefosine + thermo-therapy for CL	Miltefosine + paromomycin for VL (Africa)	SSG + PM (East Africa)*	
				DNDI-8526 (S07 series) +	DNDI-0690 +		LAmB +/- miltefosine for PKDL (Asia)	Miltefosine + paromomycin or LAmB for PKDL (Sudan)	New VL treatments (South Asia)*	
					DNDI-6899 (GSK899 DDD853651) +					New treatments for VL/HIV*
					CpG-D35 (DNDI-2319) +					New VL treatments (Latin America)*
			GSK245 (DDD1305143) +							
Chagas disease	Screening	Hit-to-lead	UW series + MT series +	Biomarkers	DNDI-6148 +		New benznidazole regimens		Benznidazole paediatric dosage forms*	
Filaria: River blindness				DNDI-6166 (CC6166) +		Emodepside + Oxfendazole +				
Mycetoma								Fosravuconazole	New treatments for mycetoma	
Dengue				Pre-clinical profiling						
HIV						SR 5FC (cryptococcal meningitis)			Super-booster for children with HIV/TB* 4-in-1 (ABC/3TC/LPV/r)* and other DAAs AHD access (incl. 5FC, LAmB for cryptococcal meningitis) 2-in-1 LPV/r pellets	
Hepatitis C									Ravidasvir* and other DAAs +	
COVID-19/ Pandemic preparedness	Nucleoside Booster		TMEM16 series + AVIDD ASAP +					ANTICOV		
Malaria »									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*	

» Implementation transferred to the Medicines for Malaria Venture in 2015

+ New chemical entity (NCE) or NCE-enabling project

* Treatments delivered by DNDi with partners

» Treatments not delivered by DNDi, but DNDi working on access